Navigation Links
Chronic pain up almost 40 percent among US workers in past decade

ause them to stay home from work.

"In my practice, I am seeing an increasing number of patients for chronic pain and hearing more patients talk about how their pain affects activities of daily living," said Charles Argoff, M.D., director and assistant professor of neurology, New York University School of Medicine, New York, New York. "They’re looking for ways to manage their pain, and there are treatments that can help such as diet and exercise, physical therapy, acupuncture and a variety of over-the-counter and prescription medications. Extended-release chronic pain medications, such as prescription ULTRAM® ER (tramadol HCl) extended-release tablets, taken once daily, have been shown to relieve moderate to moderately severe chronic pain in adults who need around-the-clock treatment for an extended period of time."

Addressing Pain at Work

There have been positive changes in the workplace in the last decade. More than two-thirds, or 66 percent, of employers surveyed now offer worksite wellness programs to employees, compared to 40 percent in 1996. But while the number of wellness programs is relatively high, the number of programs addressing chronic pain is not. Only 22 percent of wellness programs include a component about preventing or living with chronic pain conditions. "We have seen some improvement in the recognition of pain-related illness in the workplace, and that should be commended," said Dr. Gallagher. "But more U.S. businesses should invest in these wellness programs. Once employees are given the tools to better understand and manage their pain successfully, they can begin to improve many areas of their lives affected by their chronic pain."
'"/>

Source:Ruder Finn Public Relations


Page: 1 2

Related biology news :

1. FDA Clears the Way for Generic Versions of Transdermal Patches to Treat Chronic Pain
2. Chronic Sinus Infection Thought To Be Tissue Issue, Mayo Clinic Scientists Show Its Snot
3. FDA Approves New Treatment for Chronic Hepatitis B
4. Chronic jet-lag conditions hasten death in aged mice
5. Chronic fatigue syndrome impairs a persons slow wave activity during sleep
6. Farm kids almost twice as likely to die from injury as children overall
7. Hunger in America rises by 43 percent over last five years
8. Method slashes quantum dot costs by 80 percent
9. Hepatitis B accounts for 40 percent of missing Asian women
10. Vaccine provides 100 percent protection against avian flu virus in animal study
11. Oceans are 70 percent shark free
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Chronic pain almost percent among workers past decade

(Date:12/17/2014)... 15, 2014  HITLAB SM announced today ... audit to confirm its adherence to current U.S. ... enables HITLAB to conduct regulated smart device and ... for patient safety and research quality. ... quality, and delivery with innovative technology," said ...
(Date:12/17/2014)... DUBLIN , Dec. 16, 2014 Research ... announced the addition of the "Global Chemical ... http://photos.prnewswire.com/prnh/20130307/600769 ... is the increasing demand for medical sensors in ... patient data for quick and correct diagnosis during ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... RIVERSIDE, Calif. Julia Bailey-Serres , a geneticist whose ... will give a free, public lecture at UC Riverside on ... challenge of improving crop yield in the face of climate ... Solutions," the hour-long lecture will begin at 7 p.m. in ...
... This press release is available in Spanish . ... calves has been developed by Agricultural Research Service (ARS) scientists who ... nutrient the young animals need to promote optimal growth and health. ... from their mothers as they nurse during the first few days ...
... discovered a defect in cellular pathways that provides a new ... newborns, known as craniosynostosis. Mutations of the WNT ... that regulate bone formation at the stem cell level, according ... Science Signaling . "Our work contributes to the ...
Cached Biology News:Public lecture to explore solutions to the food challenge 2Public lecture to explore solutions to the food challenge 3Model developed for manipulating vitamin D levels in calves 2Stem-cell disruption induces skull deformity, UR study shows 2
(Date:12/24/2014)... Dec. 23, 2014 China Biologic Products, ... a leading fully integrated plasma-based biopharmaceutical company in ... its majority-owned subsidiary, Shandong Taibang Biological Products Co. ... from the China Food and Drug Administration (the ... As previously disclosed in the Company,s public filings, ...
(Date:12/24/2014)... 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... a Clinical Trial Application (CTA) with the ... (MHRA) seeking regulatory approval to initiate clinical trials for ... Contingent on the Company receiving CTA regulatory ... trial to assess the safety, tolerability and dose escalation ...
(Date:12/22/2014)... 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, announced ... University of Calgary in conjunction with co-authors from Kyoto ... validates the company,s ongoing clinical research using dermal sheath ... baldness. The paper entitled " Hair Follicle ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... and editorials addressing developments and pathways related to ... provocative article exploring the role of follicle-stimulating hormone ... of prostate cancer. , The article references ... that there could be a connection to prostate ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... Mass., March 31 Boston Scientific,Corporation (NYSE: ... Scientific Santa,Rosa Corp., formerly known as TriVascular, Inc., ... in Santa Rosa, California. Boston Scientific,Santa Rosa Corp. ... endovascular aortic repair (EVAR) program. Terms of the ...
... ... Year-over-Year, ALISO VIEJO, Calif., ... and services resource for,pathologists, oncologists and the pharmaceutical industry, today announced,financial ... from continuing operations was $12.4 million for the fourth quarter,of 2007, ...
... poster ... presentations, SOUTH SAN FRANCISCO, Calif., March ... clinical,trials of the company,s investigational compounds XL647, XL184, XL765 and,XL880 will be ... will be held from May 30 to June 3, 2008 in,Chicago, Illinois. ...
Cached Biology Technology:Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program 2Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program 3Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 2Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 3Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 4Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 5Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 6Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 7Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 8Clarient Announces Fourth Quarter and Year-End 2007 Financial Results 9Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting 2
Mouse monoclonal [RL13] to LAP1 ( Abpromise for all tested applications). SwissProtID: Q96NW7...
CircuLex Anti-Human S100P Polyclonal Antibody Research Focus: proliferation Storage: -20C Shipping Temperature: 4C...
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
Biology Products: